The present invention relates to compounds that are activators of the Alpha.sub.1A-Adrenergic Receptor (α.sub.1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α.sub.1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

The present invention relates to compounds that are activators of the Alpha.sub.1A-Adrenergic Receptor (α.sub.1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α.sub.1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

Chiral 1, 3-diarylimidazole salt carbene precursors, their methods of preparation, particularly transition metal complexes and their use in chemical synthesis are provided. In particular, an air and moisture stable chiral 1, 3-diarylimidazole carbene precursor Cu (I) complex has been prepared and applied to highly regio- and enantioselective Markovnikov hydroboration of unactivated terminal alkenes to form chiral boronic esters. Moreover, these new chiral NHCs can be potentially applied in various metal-catalyzed asymmetric transformations. ##STR00001##

An object is to provide an azoline ring-containing compound which achieves characteristics required for an organic EL element, such as a driving voltage, a quantum efficiency, and element lifetime in a well-balanced manner, and particularly can obtain a high quantum efficiency, for example, in a case where the azoline ring-containing compound is used for the organic EL element. The above object is achieved by an azoline ring-containing compound represented by the following general formula (1). ##STR00001## In formula (1), φ represents an m-valent group derived from an aromatic hydrocarbon having 6 to 40 carbon atoms or the like, Y represents —O—, —S—, or >N—Ar, R.sup.1 to R.sup.5 each represent a hydrogen atom or an alkyl having 1 to 4 carbon atoms, and L represents a phenylene group or the like.

An object is to provide an azoline ring-containing compound which achieves characteristics required for an organic EL element, such as a driving voltage, a quantum efficiency, and element lifetime in a well-balanced manner, and particularly can obtain a high quantum efficiency, for example, in a case where the azoline ring-containing compound is used for the organic EL element. The above object is achieved by an azoline ring-containing compound represented by the following general formula (1). ##STR00001## In formula (1), φ represents an m-valent group derived from an aromatic hydrocarbon having 6 to 40 carbon atoms or the like, Y represents —O—, —S—, or >N—Ar, R.sup.1 to R.sup.5 each represent a hydrogen atom or an alkyl having 1 to 4 carbon atoms, and L represents a phenylene group or the like.

Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associated therewith. Also disclosed is a pharmaceutical composition comprising as an active ingredient at least one compound of formula I and a pharmaceutically acceptable excipient. Also disclosed is a method of treating an eye disorder, skin disease and/or a complication thereof in a subject in need thereof by administering at least one compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.

The present disclosure relates generally to chemical compounds and, in some embodiments, to α1A-adrenergic receptor agonists and uses of such agonists in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

A photobase generator includes a compound including a first skeleton represented by the following formula (a), and a second skeleton including a nitrogen atom bonding to a bonding position of the first skeleton to form an amide group, wherein the compound generates a base, in which a hydrogen atom is bonding with the nitrogen atom of the second skeleton, by light irradiation, and the pKa of a conjugate acid of the base in water is 12 or more. In formula (a), G is a divalent aromatic group, and * represents the bonding position with the nitrogen atom.

##STR00001##

A photobase generator includes a compound including a first skeleton represented by the following formula (a), and a second skeleton including a nitrogen atom bonding to a bonding position of the first skeleton to form an amide group, wherein the compound generates a base, in which a hydrogen atom is bonding with the nitrogen atom of the second skeleton, by light irradiation, and the pKa of a conjugate acid of the base in water is 12 or more. In formula (a), G is a divalent aromatic group, and * represents the bonding position with the nitrogen atom.

##STR00001##

The present application relates to novel 3-imidazolines of formula (I′) and (I) below: (I′) (I) Wherein Ar.sub.1, Ar.sub.2, Ar.sub.3, and R.sub.1 to R.sub.6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics. ##STR00001##